I think far too much weight was put on "post swine flu" syndrome. The investment world failed to realise that the pandemic raised anti-virals from the shadows into every GP's vocabulary. Free advertising.
Stockpiling has become an established business.
Seasonal use is fast becoming an established business. Both are blockbuster markets.
We know the issues with competitor drugs, and we have a long term patent (with DS) for LANI (Laninamivir and FLUNET).
That aside, we also have BTA798 going through a large Phase IIb trial. An effective treatment for the common cold, the first one ever!
Now if this isn't an exciting stock to own, I don't know what is.
Go BTA!
BTA Price at posting:
$1.48 Sentiment: Buy Disclosure: Held
